Class Action Lawsuit Against Cassava Sciences: Key Details for Shareholders
Class Action Lawsuit Against Cassava Sciences, Inc.
On December 19, 2024, The Gross Law Firm announced a class action lawsuit against Cassava Sciences, Inc. (NASDAQ: SAVA). This lawsuit is significant for shareholders who acquired shares of the Company during the specified class period from February 7, 2024, to November 24, 2024. This legal action arises from troubling allegations related to the company's leading drug candidate, simufilam, designed to treat Alzheimer's Disease.
Background of the Case
The allegations suggest that Cassava Sciences misled its investors by providing them with material information regarding the efficacy of simufilam. According to the lawsuit, the Company communicated confidence in simufilam's potential to effectively address Alzheimer's Disease. However, on November 25, 2024, Cassava revealed the topline results from the
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.